Skip to main content
Clinical Trials/NCT02253186
NCT02253186
Completed
Not Applicable

Monocentre, Controlled, Randomized, Open Label, Clinical Study to Assess Safety and Efficacy of Auto-Adjustable MOBIDERM(R) Arm Sleeve in the Management of Upper Limb Lymphoedema During Night-time of Maintenance Phase

Thuasne1 site in 1 country40 target enrollmentStarted: September 2014Last updated:
ConditionsLymphedema

Overview

Phase
Not Applicable
Status
Completed
Sponsor
Thuasne
Enrollment
40
Locations
1
Primary Endpoint
Change in excess arm volume

Overview

Brief Summary

The objective of the study is to assess the effect of a new Armsleeve, worn during the night during maintenance phase of upper limb lymphoedema treatment in combination with Day-time usual lymphology hosiery.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Unilateral secondary upper limb lymphoedema of stage II or III, following breast cancer
  • Patients hospitalized for an intensive phase of decongestive lymphoedema therapy (DLT) for whom a decrease of lymphoedema volume has been achieved during hospitalization
  • Lymphoedema with evident pitting sign (assessed as ++ or +++)
  • Requiring compression therapy for, at least, the next 3 months.
  • Affected arm that fits with one of the 6 standard sizes of the Auto-Adjustable MOBIDERM® armsleeve provided.
  • Signed informed consent prior to any study-mandated procedure.
  • Not under any administrative or legal supervision.
  • Covered by a health insurance system

Exclusion Criteria

  • Stage I lymphoedema
  • Active cellulitis
  • Lymphoedema associated with active cancer needing acute chemotherapy
  • Motor and sensitive neurological deficiency
  • Post-operative oedema (i.e acute oedema following breast cancer-related surgery)
  • Patient participating in any other clinical study
  • Unlikely to be followed up to 3 months with clinical assessment

Outcomes

Primary Outcomes

Change in excess arm volume

Time Frame: between Day 0 and Day 30

Excess arm volume is defined as the volumetric difference between the affected upper limb compared to the contralateral upper limb, calculated with truncated cone formula

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Thuasne
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials